Overview

Metronidazole as an Adjunct of Non- Surgical Treatment of Peri-implantitis

Status:
Completed
Trial end date:
2020-12-22
Target enrollment:
0
Participant gender:
All
Summary
The use of systemic antibiotics as and adjunct to non-surgical peri-implant therapy may be an improvement in comparison to these therapies alone. The primary objective is the evaluation of significant changes in probing pocket depth between non-surgical with or without antibiotics. This is a controlled-placebo clinical trial design. Patients with osseointegrated oral implants will be selected and recruited from a university clinic. Oral hygiene instruction and non-surgical debridement at implants will be provided with ultrasonic devices and immediately after, patients will be prescribed: Group Control: A placebo with the same characteristics as the antibiotic Group Test: Systemic antibiotics (Metronidazole 250mg, 2 capsules three times a day, for 7 days Three and six months after non-surgical treatment, clinical parameters will be registered and radiographs compared using reproducible landmarks. Any adverse event will be also recorded.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Juan Blanco Carrión
Collaborator:
Osteology Foundation
Treatments:
Anti-Bacterial Agents
Metronidazole
Criteria
Inclusion Criteria:

- Older than 18 years.

- Presence of at least 1 implant diagnosed with peri-implantitis (Presence of BOP and/or
suppuration, with 2 mm of detectable bone loss after initial remodeling, and PD≥ 4 mm
as defined by Daubert et al. 2015).

- Absence of implant mobility.

- History of taking systemic antibiotics in the preceding 3 months.

- No systemic pathology that contraindicated the completion of treatment.

- The patient understands the treatment and willing to comply.

- The patient is willing to give written informed consent and can do

Exclusion Criteria:

- Pregnant.

- Metronidazole allergies

- Patients on treatment with bisphosphonates.

- Uncontrolled periodontal disease.